In this presentation Dr. Dino Prado outlines a precision‑oncology framework that combines deep multi‑omics profiling with metabolically‑driven “primers” (insulin, fasting, oxygen/ozone, inflammatory and hypoxic pathway modulators) to enable genetically targeted fractionated chemotherapy (GTFC). He revisits early work on insulin potentiation therapy (IPT), noting its inconsistent efficacy and safety when used without biomarker guidance. Over 25 years, his team refined a metronomic micro‑dosing approach that deliberately releases damage‑associated molecular patterns (DAMPs) such as calreticulin, ATP and HMGB1 to trigger immunogenic cell death and stimulate a patient’s own immune response. The workflow begins with extensive DNA, RNA, and spatial immune profiling (hundreds to thousands of markers) to generate heat‑maps that identify actionable targets and the appropriate primers. Custom‑compounded on‑label, off‑label, repurposed drugs, and nanoparticle‑formulated phytotherapeutics are then delivered in low‑dose, fractionated schedules timed to the metabolic primer’s therapeutic window. The speaker emphasizes that correct biomarker selection, precise timing, and metabolic preparation (e.g., fasting‑mimicking diets, glucose monitoring) are essential for the primers to improve drug delivery, reduce systemic toxicity, and enhance immune activation. Clinical observations suggest that up to 90 % of patients previously received ineffective chemotherapy, whereas GTFC, guided by the described algorithms, yields higher response rates, better tolerability, and the ability to cross the blood‑brain barrier for brain metastases. The overarching goal is to shift from cytotoxic killing to an immune‑centric strategy that achieves durable remission.
Chapters
What if a simple peptide hormone could help your treatment hit harder with less drugs? Today I'll show you how insulin fasting oxygen primers can support precision oncology immunocentric planning so the care is smarter, safer and more personalized. I'm Dr. Dino Prado and for the last 25 years my team and I have helped thousands of patients who have failed standard of care. Oncology we use multi omics and deep level testing. We use thousand plus markers instead of the typical 24. Next generation sequencing, DNA transcriptomics, RNA immune profiling with spatial biology to choose the exact targets that deliver micro dose fractionated treatments with the right primers to push tumors towards an immunogenic cell death. Not just managing the cancer, but getting rid of it. Our goal with every patient is less guesswork and more life. So let's get started here. The peptide hiding in plain sight is insulin. And here's a peptide that makes a big difference. People aren't aware of insulin. Insulin is a peptide that in the early 2000s we worked for many years using a treatment called insulin potentiation therapy. It's actually a therap a lot of integrative doctors still use across the world delivering chemo dosed with insulin to make the low dose chemotherapy more effective. So we saw this treatment called IPT that could help patients. But it always wasn't consistent in the way it worked. It was safe, but it didn't do the job we wanted to with most of the patients. It worked on some, but not all. We treated many patients and under physician supervision we saw no issues. Here's how it worked. A patient's glucose dropped with insulin we reach what was called the therapeutic moment. And then the chemotherapy was delivered, improving the drugs deliver delivery to the tumor. So IPT became an alternative approach with limited benefit but fewer side effects when carefully monitored. Now let's talk about why insulin ever made such a difference. Many tumors have high glucose, hunger and overexpression of insulin pathways elements like IGF1. And in small prospective studies like breast cancer, adding insulin to methotrexate improved response signals versus methyltrexate alone. It wasn't definitive, but it showed promise. So we used it and it was helpful for a lot of our patients as a primer, not a cure. As our precision oncology improved over the years, we realized it only made sense when specific biomarkers were present. That's when we watched blood sugar closely and only used it selectively. Here's the big idea and what we've seen have great success with our patients. It's called gtfc. From those early days of insulin potentiation therapy lessons, we developed this metronomic microdosed approach with the focus of releasing dams damage associated molecular patterns, stimulating the immune system. So, so here's the most important piece we learned and it's the most critical piece. No matter what you do, it's selecting the right treatments. It doesn't matter whether you're using IPT insulin potentiation therapy or the National Comprehensive Cancer Network guideline, chemotherapies or anything else. If you do not have the right treatments or the right regimens, it does not work. So getting deep mapping is critical. That's where precision oncology starts the DNA next generation sequencing hundreds of markers, the RNA transcriptomics, thousands of markers, and immune spatial biology. With profiling allowing us to see the tumor, 3D microenvironment and what the tumor needs to turn on its immune system to shut down. Using these heat maps and algorithms, we select the correct treatments. So that's number one, no matter what you do. And what we learned early on was even when we used companies that were from Greece and other parts of the world, we just didn't see the benefits we did until we had the laboratory data to look at all of this information and customize it in our algorithms for patients. Now that we had the right targets, we needed fractionated low dose delivery micro dosing. The key here was looking at the dam damage associated molecular patterns to stimulate immunity. Using specialized nanoparticle deliveries as adjuvants, we saw a dynamic improvement in patient outcomes. This is very different than insulin potentiation therapy. We might use insulin only if the right markers are present. We first pick the right agents from on label, which we have to custom make in our pharmacies, off label repurposed drugs, immune modulating options, phytotherapeutics that are nanoparticle. And then we deliver them when you add the right primer. And here's where the primers come in. Think of it as like priming the surface before you're painting. In those specific cases, insulin at the right time improves drug delivery and immune signaling. That's the logic behind genetically targeted fractionated chemotherapy, which we've published on. Years ago, patients started seeing great improvements in our care. And along with a metabolic preparation and healthy diet and getting rid of the refined carbohydrates and sugars, we were able to get them into a fasting window. And when they had these right targets for the right primer of insulin, we saw greater absorption of chemotherapy. So if the biomarker fits. We can use the insulin alongside the chemo, but not in all cases. Research continues to show that metronomic dosing, these micro doses of chemotherapy shift the tumor's biology, reducing the blood supply to the tumor and enhancing the release of the dams. The damage associated molecular patterns with fewer side effects than standard chemotherapy. By far over time, our data showed nearly 90% of the patients were on the wrong chemotherapy before they came to us. And that's where our precision targeting changed everything. Metabolic press pulse, the delivery of the chemotherapy, the low dose chemotherapy timed perfectly makes all the difference, showing that fasting and fasting mimicking diets, make chemotherapy more tolerable and can enhance its effects in select patients. With molecular markers showing IGF1 activity, we carefully time the use of insulin peptides during treatment. And when done correctly, this approach changes outcome. So when insulin primer comes in, these cancer cells become hungry, allowing the micro dose chemotherapy to enter and boom, the trojan horse is deliver. That's the true press pulse model. That's really the key of precision because you have the right agents and the right metabolic primers. Not just blocking glutamine and sugar, but integrating drug targeting with an immune centric precision. Because at the end of the day, you're going to need the immune system. It's the first and last defense against cancer. Now stick with me here. Why primers matter. This is really basic. A lot of people don't think of this. Most chemotherapy, only 2 to 5% actually make it to the tumor. That means 95% is going to organs and the central nervous system causing toxicity. Toxicity. So we want to look at tools that help us deliver the chemotherapy to the tumor and less of it to healthy normal cells. To fix this, we use primers, but insulin is only one of them and not always used. Only if the biomarkers fit and glucose is tightly monitored and it's a target for the patient based on our testing do we use it. But let me share with you other primers that are used. Ozone acts as a primer by increasing oxygenation and modulating the redox, balancing and cytokine signaling, prepping the tumor's microenvironment for better results. So if patient has hypoxia inducing factor alpha and all these pathways that show low oxygen, this becomes critical. The fasting window supervised with the right tolerance for care. Now we can amplify the drugs using different primers. We have inflammatory primers, we have hypoxic pathway primers. Using these different primers helps us to target the care individually for Each patient. So genetically targeted fractionated chemotherapy is not insulin potentiation therapy. It was born from that two and a half decades ago, but has advanced significantly because of the data, the targeting, the deep mapping and the selection of the primers and the right treatments going together. Think of it this way. The primer is like a kryptonite. When you map it out properly, it creates like a weakness for the cancer. So you can deliver the trojan horse. So you get the chemotherapy that's perfectly selected for that patient to get delivered into the tumor and for the patient to get the response you want. But then it's done in the right concentrations so that you get this immunogenic cell death, the damps. This is the ultimate goal, is the stimulation of the immune system. You'll always hear me say we aim for the immune system to do the work. That's what you need for long term remission. Unlike standard chemotherapy where they pour high doses and it wipes out your immune system and causes weakening of the body, this strengthens your immune system and it does it with the right markers. Damps are so important. These are the signals that call in your immune system. Calriculin, ATP, HMGB1. These markers alert your dendritic cells and T cells and train them to go after cancer everywhere else in the body. And if you use an immunocentric care, where the treatment is designed to not only kill the cancer, but stimulate the immune system, at the end of the day, that's the key. That's the power of genetic genetically targeted fractionated chemotherapy. So let's put it all together. Precise mapping with heat maps telling us exactly what the cancer needs and what's going to work best for the patient. Then, no guesswork. We look at what we need to do here. On label drugs, off label repurposed drugs, nanoparticle phytotherapeutics and immune modulators all combined for that patient and custom built for them. Design the micro dose delivery to stress the tumors and protect the body's immune system, but teach the immune system to go out and kill the cancer everywhere else in the body. Then, and only then, you add the primers based on the data algorithms that we have, whether that be insulin or oxygen or fasting, which is common in patients, but inflammatory pathways, hypoxic pathways, allowing us to better target treatment. We aim for an immune kill and the DAMPS guide us. And so this is the difference with genetically targeted fractionated chemotherapy. We can also add special techniques to get past the blood brain barrier. When we have brain metastases it's so powerful. We've learned over the years, and we're so good at it, and we've been doing it for so long that we've mastered the delivery of this metabolic approach, this bimodal approach of taking care of the metabolic side of cancer and also going after the mutational side while stimulating the immune system. There's a lot more to it than this, but this gives you the idea and the powerful peptides and primers that can play a role as adjuvants to helping cancer treatment be effective. I hope this was helpful, and may the Lord bless you on your journey to healing. Bump.
